Clinical trials: Filovirus Disease, open to volunteers
Ebola Virus Disease
Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
Ebola virus disease (EVD) is emerging regularly in various African countries for various reasons: during contact with mortal remains, during an unsafe burial or following the viral dissemination around a recovered patient.
- Trial name
- NCT05202288
- Testing
- Ervebo, Inmazeb
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Ebola Virus Disease
Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC
The goal of this randomized controlled trial is to investigate whether individuals in DRC previously vaccinated with Zabdeno/Mvabea® or Ervebo® vaccine schedules against Ebola virus can be safely and adequately boosted with…
- Trial name
- EBO-BOOST (NCT06126822)
- Testing
- Zabdeno® booster, Ervebo® booster
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Marburg Virus Disease (MVD)
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of a Preventative Vaccine for Marburg Virus (mRNA-1519) in Healthy Adult Participants
The main objective of this trial is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1519
- Trial name
- NCT07919210
- Testing
- mRNA-1519
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Filovirus Disease
Study of Filovirus Disease Morbi-mortality
Filoviruses, including Ebola and Marburg, cause hemorrhagic fevers associated with high mortality and still limited scientific literature, in particular for some rare species such as the Bundibugyo virus.
- Trial name
- TEMBO (NCT07821580)
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ebola Virus Disease
EBOla Post-Exposure Prophylaxis
EBO-PEP is a multicentre, multi-epidemic, phase III, comparative, controlled, randomised, strict superiority trial in two unblinded parallel arms.
- Trial name
- EBO-PEP (NCT06841614)
- Testing
- Ervebo, Inmazeb
- Where
- 4 sites in Democratic Republic of the Congo, Guinea and 2 more
- Volunteers
- 160 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Sudan Virus Disease
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health.
- Trial name
- NCT07565090
- Testing
- rVSVΔG-SUDV-GP
- Where
- 3 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Ebola Hemorrhagic Fever
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - DRC
This study aims to validate the clinical performance of a newly developed isothermal nucleic acid amplification bioassay module for EBOV.
- Trial name
- NCT07688083
- Testing
- DECIPHER bioassay
- Volunteers
- 100 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Ebola, Bundibugyo Virus Disease (BVD)
BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies
The BRAVO study (Bundibugyo: Respondre Avec la Vaccination, "On est ensemble") was developed in response to the 2026 Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo (DRC).
- Trial name
- BRAVO (NCT07903350)
- Testing
- ERVEBO Vaccination
- Where
- Democratic Republic of the Congo
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Epicentre
Ebola Hemorrhagic Fever, Lassa Hemorrhagic Fever
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA
This study aim to validate the clinical performances of two newly developed isothermal nucleic acid amplification bioassays modules for EBOV and LASV.
- Trial name
- NCT07681752
- Testing
- FORTIFIEDx and DECIPHER bioassays
- Volunteers
- 150 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Ebola Hemorrhagic Fever, Bundibugyo Virus Disease
Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo
Bundibugyo virus (BDBV) causes severe and often fatal outbreaks of Bundibugyo virus disease (BVD). No vaccine against BDBV is licensed.
- Trial name
- TUMAINI (NCT07842107)
- Testing
- Candidate BDBV vaccine, Active comparator
- Where
- Democratic Republic of the Congo
- Volunteers
- 3,620 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden